Emodin suppresses interleukin-1β induced mesangial cells proliferation and extracellular matrix production via inhibiting P38 MAPK

被引:63
作者
Wang, Rong [1 ]
Wan, Qiang [1 ]
Zhang, Ying [1 ]
Huang, Fangfang [1 ]
Yu, Kezhou [1 ]
Xu, Dongmei [1 ]
Wang, Qun [1 ]
Sun, Jing [1 ]
机构
[1] Shandong Univ, Shandong Prov Hosp, Dept Nephrol, Shandong, Peoples R China
关键词
emodin; mesangial cells; glomerulosclerosis; P38; MAPK; ACTIVATED-PROTEIN-KINASE; FIBRONECTIN EXPRESSION; FEEDING IMPAIRS; MAJOR ACTIVATOR; RENAL FIBROSIS; RAT; ANGIOGENESIS; ACCUMULATION; PURIFICATION; INVOLVEMENT;
D O I
10.1016/j.lfs.2007.04.010
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Previous findings indicate that emodin has anti-proliferation and anti-fibrosis effects on several cell lines. In this study, we investigated the effects of emodin on IL-1 beta induced proliferation of mesangial cells (MCs) and on their production of extracellular matrix (ECM), and explored the possible mechanisms. To test the therapeutic effect of emodin on progressive renal disease, we administered emodin to rats in renal failure models induced by subtotal nephrectomy, the renal function was analyzed. Our results showed emodin significantly suppressed IL-1 beta induced MC proliferation and arrested the cell-cycle progress in vitro. Fibronectin and collagen W production by MC were significantly reduced after emodin treatment. P38 mRNA, protein levels of P-P38, P-MKK3/6 and P-MKK4 were quantified. We observed no alterations of P38 expression and P-MKK4 protein content; however, protein levels of P-P38 and P-MKK3/6 significantly decreased after emodin treatment. In the renal failure models, after administration of emodin for eight weeks, the rat renal lesions were significantly ameliorated, as evidenced by the decreased blood creatinine, urea, and the 24-hour urine protein. In conclusion, emodin suppresses IL-1 beta induced MC proliferation and ECM production in vitro. We hypothesize that this is achieved by inactivating MKK3/6 and P38. Emodin ameliorates renal failure in subtotal nephrectomized rats, which suggests a potential role of emodin in the treatment of progressive renal diseases. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:2481 / 2488
页数:8
相关论文
共 37 条
[1]  
Becker GJ, 2001, J NEPHROL, V14, P332
[2]   Anti-inflammatory effects of emodin from Ventilago leiocarpa [J].
Chang, CH ;
Lin, CC ;
Yang, JJ ;
Namba, T ;
Hattori, M .
AMERICAN JOURNAL OF CHINESE MEDICINE, 1996, 24 (02) :139-142
[3]   Stimulation of pro-α1(I) collagen by TGF-β1 in mesangial cells:: role of the p38 MAPK pathway [J].
Chin, BY ;
Mohsenin, A ;
Li, SX ;
Choi, AMK ;
Choi, ME .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2001, 280 (03) :F495-F504
[4]   Purification and cDNA cloning of SAPKK3, the major activator of RK/p38 in stress- and cytokine-stimulated monocytes and epithelial cells [J].
Cuenda, A ;
Alonso, G ;
Morrice, N ;
Jones, M ;
Meier, R ;
Cohen, P ;
Nebreda, AR .
EMBO JOURNAL, 1996, 15 (16) :4156-4164
[5]   Progression in chronic kidney disease [J].
Eddy, AA .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2005, 12 (04) :353-365
[6]   Interleukin-1β induces chronic activation and de novo synthesis of neutral ceramidase in renal mesangial cells [J].
Franzen, R ;
Pautz, A ;
Bräutigam, L ;
Geisslinger, G ;
Pfeilschifter, J ;
Huwiler, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (38) :35382-35389
[7]   Interleukin-1β-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells [J].
Guan, ZH ;
Buckman, SY ;
Miller, BW ;
Springer, LD ;
Morrison, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (44) :28670-28676
[8]   Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition [J].
Ha, Hunjoo ;
Kim, Myoung Soo ;
Park, Jehyun ;
Huh, Joo Young ;
Huh, Kyu Ha ;
Ahn, Hyung Joon ;
Kim, Yu Seun .
LIFE SCIENCES, 2006, 79 (16) :1561-1567
[9]  
Haas CS, 1999, J NEPHROL, V12, P405
[10]   IMMUNOSUPPRESSIVE EFFECT OF EMODIN, A FREE-RADICAL GENERATOR [J].
HUANG, HC ;
CHANG, JH ;
TUNG, SF ;
WU, RT ;
FOEGH, ML ;
CHU, SH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 211 (03) :359-364